WHAT IS CLAIMED IS:

1. Use of a liposomal composition in the manufacture of a medicament for treating joint pain in a human subject with osteoarthritis in long term, wherein the medicament is intra-articularly administered to the human subject with repeat doses, the liposomal composition comprises an effective amount of intra-articular corticosteroid or a pharmaceutically acceptable salt thereof and a lipid mixture, wherein administration of the repeat doses of medicament does not trigger signs and/or symptoms of adrenal insufficiency in the human subject.
2. The use of claim 1, wherein the repeat doses of medicament are administered with a dosing interval selected from the group consisting of 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, and 36 weeks.
3. The use of claim 1, wherein the intra-articular corticosteroid or the pharmaceutically acceptable salt thereof is released over a duration selected from the group consisting of 52 weeks, 53 weeks, 54 weeks, 55 weeks, 56 weeks, 57 weeks, 58 weeks, 59 weeks, 60 weeks, 61 weeks, 62 weeks, 63 weeks, 64 weeks, 65 weeks, 66 weeks, 67 weeks, 68 weeks, 69 weeks, 70 weeks, 71 weeks, 72 weeks, 73 weeks, 74 weeks, 75 weeks, 76 weeks, 77 weeks, 78 weeks, 79 weeks and 80 weeks.
4. The use of claim 1, wherein the intra-articular corticosteroid or the pharmaceutically acceptable salt thereof is released at a rate that does not adversely suppress the hypothalamic-pituitary-adrenal axis (HPA axis).
5. The use of claim 1, wherein the intra-articular corticosteroid or the

pharmaceutically acceptable salt thereof is released at a rate that does not adversely suppress cortisol levels in the human subject.

6. The use of claim 1, wherein the intra-articular corticosteroid or the pharmaceutically acceptable salt thereof is selected from the group consisting of dexamethasone sodium phosphate, dexamethasone, betamethasone, betamethasone sodium phosphate, betamethasone acetate, betamethasone dipropioinate, betamethasone valerate, mometasone furonate, triamcinolone acetonide, triamcinolone hexacetonide, triamcinolone diacetate, methylprednisolone sodium succinate, methylprednisolone acetate, prednisolone tebutate, hydrocortisone acetate, alclometasone dipropionate, halcinonide, fluocortolone, fluocinolone acetonide, and combinations thereof.
7. The use of claim 1, wherein the intra-articular corticosteroid is dexamethasone sodium phosphate (DSP) with an effective amount ranging from about 6 mg to about 18 mg.
8. The use of claim 7, wherein the effective amount of DSP is about 12 mg.
9. The use of claim 1, wherein the lipid mixture comprises dioleoylphosphatidylcholine (DOPC) and dioleoylphosphatidylglycerol (DOPG).
10. The use of claim 9, wherein the lipid mixture further comprises cholesterol at a mole percent of about 10 to about 33 based on the total amount of the lipid mixture.
11. The use of claim 1, wherein the osteoarthritis is knee osteoarthritis.